Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region "Living With a Myeloma in West-Occitanie" (VAMOS)

Therapeutic and Support Oncologic Medical Care Evaluation in Patients With Multiple Myeloma in West-Occitanie Region. Factors Influencing Medical Care and Predictive and Prognostic Impact.

Actually very few real life data are available for patients with multiple myeloma (MM), whereas they're playing a more and more important role in health care decisions. Treatments choice for medical care of patient with MM depends of their age, their general status, their eligibility to high dose treatment (autograft), and also based on cytogenetic risk (standard/high risk). Therapeutic strategies are multiple and based on drugs associations including proteasome inhibitors, immuno-modulators and monoclonal antibodies.

Therapeutic medical care objective is to improve quality and response duration through more effective induction schemas, systematic consolidation for patients who have undergone high dose therapy and/or maintenance treatment, ensuring patients safety and well-being in the health care pathway.

Quality of life evaluation has to take in consideration disease outcome and secondary effects impact from treatments prescribed for MM.

With clinical trials, new therapeutic strategies are proposed with innovative drugs but participants are selected and do not represent all patients with MM. Therefore, there is a large gap between clinical trials and real life data.

That's why the CHU Toulouse intends to set up a prospective cohort to evaluate the health care pathway of patients with MM in West-Occitanie region and studies impact of treatments prescribed on the disease and on the patients' quality of life.

With this research, standard of care practices for patients with MM will be followed, prognostic scores and clinical trials results will be validated in real life, impact of outpatient support procedure will be assessed (AMA procedure) and sociodemographic/quality of life data will be available for research teams.

Study Overview

• Status: Recruiting
• Conditions: Multiple Myeloma
• Intervention / Treatment: Other: quality of life questionnaires (EORTC QLQ-C30 ; EORTC QLQMY20 ; EQ-5D-5L ; Cohen's stress scale)

Detailed Description

Primary objective :

Describe health care pathways of patients with MM living in West Occitanie according to socio-demographic patients' caracteristics, their comorbidities and their initial disease severity. These pathways will be described until the patients' death if the death occurs before the end of their follow-up in this study.

Secondary objectives :

• The best response at each line of therapy
• The progression free survival and overall survival
• Quality of life of patients with MM along their health care pathway
• Second primary malignancy and neuropathy grade 3 or more occurrence during patients'care
• Socio-demographic, clinic and biology factors identification to predict response to treatments, progression free survival, overall survival and quality of life.

Study size calculation :

With the hypothesis of 80% of patients informed about the study will agree to participate and will accept to have their health care data collected, and with 500 to 550 patients' medical files presented each year for MM care to West Occitanie multidisciplinary committee meeting (approximately 400 different patients), a 5-years recruitment period will lead to 1600 patients enrollment.

This size will be able to generate enough precisions for descriptive analyses. Indeed, as example, with a percentage of 50%, conservative situation to estimate percentages, expected precision should be more or less 2.5% according to Clopper-Pearson exact method.

Precision of more or less 5% should be also obtained for sub-groups of 400 persons.

• Study Type: Observational
• Enrollment (Estimated): 2000

Contacts and Locations

• Study Contact: Name: Aurore PERROT, MD; Phone Number: +33 +33 5 31 15 64 90; Email: perrot.aurore@iuct-oncopole.fr
• Study Contact Backup: Name: Sandrine ROLLET, PM; Phone Number: +33 +33 5 31 15 63 39; Email: rollet.sandrine@iuct-oncopole.fr

Study Locations

• France
  • West-Occitanie
    • Toulouse, West-Occitanie, France, 31059
      • Recruiting
      • IUCT-Oncopole - Toulouse University Hospital
      • Contact: Sandra BERNARD, PM; Phone Number: +33 +33 5 61 77 85 73; Email: bernard.s@chu-toulouse.fr
      • Principal Investigator: Aurore PERROT, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Adult patients with a diagnosis of symptomatic multiple myeloma and living in the west-Occitanie region.

Description

Inclusion Criteria:

• Patient living in the West-Occitanie region
• Patient with a diagnosis of symptomatic multiple myeloma (Rajkumar et al, Lancet Oncology 2014)

Exclusion Criteria:

• Patient opposed to this research
• Patient under legal protection

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Treatment lines and procedures followed by the patients	Different treatment lines and procedures followed by the patients with drugs involved, number of cycles performed in each treatment phase (induction, consolidation, maintenance) and for each therapeutic line	5 to 10 years
Transplants	Transplants carrying out	5 to 10 years
Treatments discontinuation	Reasons for treatments administered discontinuation	5 to 10 years
Therapeutic medical care description	Supportive care and the type of care set up	5 to 10 years
Unconventional alternative medicine	Use and description of unconventional alternative medicine	5 to 10 years
Outpatient support structure	Support from an outpatient support structure (AMA)	5 to 10 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Best response (BR)	BR evaluated according to IMWG criteria at each treatment line. This takes into account the MRD as part of the response criteria since this date.	5 to 10 years
Progression-free Survival (PFS)	Time between date of first intake of treatment until 1st progression according to the IMWG criteria or until death if it occurs before progression	5 to 10 years
PFS after the second therapeutic line	Time between date of 1st dose of treatment until 2nd progression according to the IMWG criteria or until death if it occurs before the 2nd progression.	5 to 10 years
Overall Survival (OS);	Time between date of first intake of treatment and death from any cause.	5 to 10 years
Quality of life (QOL) during the treatment course	QOL assessed by the EORTC questionnaires QLQ-C30, QLQMY20 and EQ-5D-5L, at the start of treatment then at the end of induction and consolidation periods and once a year for patients undergoing maintenance for the first 2 lines of treatment.	5 to 10 years
Second primary cancers (SPC) and grade 3 and higher neuropathies	-SPC and grade 3 and higher neuropathies (depending on the applicable version of the CTCAE)	5 to 10 years

Collaborators and Investigators

• Sponsor: University Hospital, Toulouse
• Collaborators: Sanofi; Institut National de la Santé Et de la Recherche Médicale, France; Takeda
• Investigators: Principal Investigator: Aurore PERROT, MD, IUCT-Oncopole - Toulouse University Hospital

Study record dates

Study Major Dates

• Study Start (Actual): December 15, 2021
• Primary Completion (Estimated): June 1, 2031
• Study Completion (Estimated): June 1, 2031

Study Registration Dates

• First Submitted: May 4, 2021
• First Submitted That Met QC Criteria: May 10, 2021
• First Posted (Actual): May 17, 2021

Study Record Updates

• Last Update Posted (Actual): April 29, 2026
• Last Update Submitted That Met QC Criteria: April 28, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Multiple Myeloma; Quality of life; Real life; Health care pathways
• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Neoplasms; Immune System Diseases; Neoplasms by Histologic Type; Hematologic Diseases; Lymphoproliferative Disorders; Immunoproliferative Disorders; Neoplasms, Plasma Cell; Hemostatic Disorders; Paraproteinemias; Blood Protein Disorders; Hemorrhagic Disorders; Hemic and Lymphatic Diseases; Multiple Myeloma
• Other Study ID Numbers: RC31/20/0482; N° ID RCB: 2020-A03527-32 (Registry Identifier: Numéro ID RCB)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No